Crossmark

Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial

Crossref DOI link: https://doi.org/10.1186/s13023-019-1195-1

Published Online: 2019-09-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Aram

Choi, Jin-Ho

Sohn, Young Bae

Eom, Yunae

Lee, Jiyoon

Yoo, Han-Wook

Jin, Dong-Kyu https://orcid.org/0000-0003-4162-2706
Funding

Funding for this research was provided by:

LG Chem, Ltd.
License Information

Text and Data Mining valid from 2019-09-11

Version of Record valid from 2019-09-11
More Information

Article History

Received: 10 May 2019

Accepted: 4 September 2019

First Online: 11 September 2019

Ethics approval and consent to participate

: The study was approved by the institutional review board at 3 study sites. Written informed consent was obtained from the legally authorized representatives of all the participants.

: Not applicable.

: YE and JL are employed by LG Chem, Ltd. The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below